Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds.

The bonds have a maturity period of six years from the issued date.

Headquartered in China, Shanghai Shyndec is a manufacturer of active pharmaceutical ingredients (APIs), chemical raw materials, and finished drug products.

Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.

Based in the US, Aprecia Pharmaceuticals is a drug delivery technology company, while Cycle Pharmaceuticals is a UK-based pharmaceutical company.

“Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.”

Japanese pharmaceutical products manufacturer Daiichi Sankyo Company and Puma Biotechnology have signed a pre-clinical research agreement with Memorial Sloan Kettering Cancer Center (MSK).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Daiichi Sankyo’s investigational drug conjugate DS-8201 and Puma Biotech’s tyrosine kinase inhibitor neratinib (NERLYNX) will be investigated in HER2-mutated or HER2-positive solid tumours, as part of the agreement.

Veru has acquired the global rights for oral granule formulation solifenacin from Camargo Pharmaceuticals Services.

Solifenacin is the API in VESIcare, a drug used for treating overactive bladder in men and women.

The acquisition allows Viru to enhance its novel urology drugs portfolio.